Company: PFSA
Filing Date: 2025-08-22
Form Type: S-1/A
Source: 0001213900-25-079829
Chunk: 282

Company: Profusa, Inc.
Filing Date: 2025-08-22
Form: S-1/A
Chunk 282
---
604,651 |   |     |              | 5,600,741 |   |
| Net loss per share attributable to common stockholders – basic and diluted:    |     | $            |     (1.65 | ) |     | $            |     (1.84 | ) |

The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive:

|                                  |     |  Years ended 
 December 31, |      |     |            |      |
|                                  |     |         2024 |      |     |       2023 |      |
| Convertible preferred stock      |     |   17,863,934 |      |     | 17,863,934 |      |
| Convertible notes payable        |     |    3,363,624 |      |     |  2,251,941 | ​(1) |
| Convertible loans                |     |            — | ​(2) |     |          — |      |
| Options to purchase common stock |     |    2,972,055 |      |     |  2,982,055 |      |
| Total                            |     |   24,199,613 |      |     | 23,097,930 |      |

____________

(1)

(2)

Note 12 — Government Grant Revenue Government grant revenue consists of amounts the Company earns under grants from two government agencies: NIH and DARPA. These grants are provided either in the form of expense reimbursement (expense reimbursement grants) or on a fixed fee basis (fixed fee grants). Under the expense reimbursement grants the government agencies reimburse us for a portion of our expenses (allowable expenses) that have been incurred in a given period on the basis of reports that the Company provides to these agencies. Fixed fee grants are awarded for specific research and development programs undertaken by us. Under these grants the Company receives milestone payments from the government agencies upon our submission and approval by the government of agreed upon deliverables, consisting primarily of the documented results of the specific research and development programs.

F-26

PROFUSA, INC. AND SUBSIDIARY
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

Note 13 — Income Taxes

Income taxes in the Company’s combined financial statements have been calculated on a separate tax return basis.

|                                            |     | Year Ended December